NAD Recommends L’Oréal Discontinue “#1 Dermatologist Recommended” Claim for CeraVe; Advertiser to Appeal

For Immediate Release
Contact: Abby Hills, Director of Communications, BBB National Programs

703.247.9330 / press@bbbnp.org

New York, NY – January 28, 2021 – The National Advertising Division (NAD) of BBB National Programs recommended that L’Oréal USA, Inc. discontinue claims that CeraVe is the “#1 dermatologist recommended skincare brand” and that it is the “#1 recommended non-OTC moisturizer for acne-prone skin.” 

The claims at issue, which appeared in online advertising, social media, and on in-store materials for CeraVe skincare products, were challenged by Johnson & Johnson Consumer Inc., the maker of competing Neutrogena brand facial and body cleansers, moisturizers, and sunscreens.

In support of its claim that CeraVe is the “#1 dermatologist recommended skincare brand,” L’Oréal relied on data from an online survey of approximately 1,500 dermatologists, which recorded the number and percentage of dermatologists’ average weekly recommendations by brand name in the surveyed categories. For certain conditions like acne, the survey asks about brand recommendations in multiple product categories, for example, “Acne: Cleansers” and “Acne: Moisturizers/Treatments.” Certain survey categories are identified by particular skin conditions like “Eczema.” Other survey categories call for brand recommendations in a particular product category, which in some instances is tied directly to a specific condition (e.g., “Wart Remover”) and in other instances is not directly tied to a particular condition (e.g., “Male Oriented Skin Care Products”).

L’Oréal relied on the results from 33 of the 48 categories in the survey, which it considered relevant to consumers’ understanding of “skincare,” and omitted those for which dermatologists did not report any recommendations in the 12 months ending December 2019, March 2020, or May 2020, and those it deemed irrelevant to the common conception of “skincare.”

After evaluating the methodology of the survey, although NAD did not take issue with its general methodology or with the particular categories surveyed, NAD determined that it was not reliable because it did not adequately instruct respondents not to duplicate their total average weekly recommendations between and among categories and, therefore, created the possibility of double-counting or that dermatologists would record the same brand recommendation in different categories if the recommendation for a particular indication is applicable in multiple categories. 

NAD further concluded that in the absence of more explicit instructions, the potential for double counting is increased due to the format of the survey and its degree of inherent imprecision. For these reasons, NAD recommended that L’Oréal discontinue the claim that CeraVe is the “#1 dermatologist recommended skincare brand.”

NAD also recommended that L’Oréal discontinue the claim that CeraVe is the “#1 recommended non-OTC moisturizer for acne-prone skin.” 

NAD noted that while L’Oréal’s use of the term “non-OTC” is an effort to accurately distinguish its products from acne drug products sold without a prescription, the claim is based on survey data which called for dermatologists’ Average Weekly Recommendations for “OTC” Acne Moisturizer/Treatments and not “Non-OTC” products. NAD determined that “Non-OTC” may also be understood by consumers as a reference to prescription drug products instead of cosmetic products like CeraVe’s. Without a more accurate descriptor such as “non-prescription,” NAD concluded that there was a poor fit between the substantiation and the claim as it appears.

Nothing in NAD’s decision precludes L’Oréal from making truthful and non-misleading claims about dermatologists’ recommendations for its skincare products based on reliable survey data.

In its advertiser’s statement, L’Oréal stated that it will “appeal NAD’s decision that the underlying survey was not sufficiently reliable to support a ‘#1 Dermatologist Recommended Skincare Brand’ claim for the CeraVe brand without revised instructions.” L’Oréal further stated that it “will take NAD’s recommendations into account for future advertising” regarding the claim that CeraVe is the “#1 recommended non-OTC moisturizer for acne-prone skin.”

###

About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.    

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary